ABSTRACT: #102
The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4 cancer antigen, achieved responses in patients with multiple solid tumor types, including #102synovial sarcoma, head and neck cancer and lung cancer, according to results from a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
Among 38...
ABSTRACT: #109
The targeted therapy pralsetinib appears to have high response rates and durable activity in patients with a broad variety...
Patients with advanced non-small cell lung cancer (NSCLC) and the MET exon 14 (METex14) skipping mutation had a 46.5% objective response rate...
ABSTRACT: #5003
In an international trial led by researchers at The University of Texas MD Anderson Cancer Center, treatment with MK-6482, the small molecule inhibitor of hypoxia-inducible factor (HIF)-2a was well tolerated and resulted in clinical responses for patients with von Hippel-Lindau disease (VHL)–associated renal cell carcinoma (RCC).
The results of the Phase II trial were shared today in an oral presentation...
ABSTRACT: #7500
A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was found to be effective...
The University of Texas MD Anderson Cancer Center and Innovent Biologics, Inc. today announced a strategic collaboration agreement to co-develop...
Patients with advanced BRCA-mutated breast cancer found no overall
survival benefit with talazoparib
ABSTRACT: CTO71
New data from the Phase III EMBRACA trial led by researchers at The University of Texas MD Anderson Cancer Center...
ABSTRACT: DDT01-03
In a first-time disclosure of IPN60090, a small-molecule inhibitor of the metabolic enzyme glutaminase (GLS1), researchers...
Guillermina Lozano, Ph.D., chair of Genetics at The University of Texas MD Anderson Cancer Center, has been elected as...
The University of Texas MD Anderson Cancer Center is committed to keeping our patients, our workforce members and our community safe throughout...